The studies were performed in the laboratory of Dr. Gene Olinger at the United States Army Medical Research Institute of Infectious Diseases , Frederick, MD online pharmacy .
Lundbeck A / S and Teva Pharmaceutical Industries Ltd. announced new long-term data on Azilec released in the TEMPO study and its open-label extension. The results confirm the long-term efficacy, safety and tolerability of Azilec in patients with Parkinson ‘s disease and further demonstrate the benefits obtained with early treatment initiation. The data was 2010 issue 2010 issue of the International Journal of Neuroscience. ‘The high proportion of patients , which indicates Azilec monotherapy after two years in the study earlier earlier from Azilec in the treatment paradigm offers us an effective and safe alternative to the use of dopamine agonists for longer period, said Mark Lew, lead investigator and vice chair of the department of neurology and director the Department of movement Disorders, Keck School of Medicine of the University of Southern California. Parkinson’s disease patientsngs provide additional support for a growing approach to treating patients with PD earlier shown in the course of their disease as well as in the ADAGIO study. ‘.
Vesicles bacteria at the material of transportation to immune cells Touch During one Legionella infection the bacteria are be swallowed up immune cells and connected through a membrane into the cell interior. Legionella protects itself from being destroyed by letting go of proteins to reprogram the human cells and use them for their own purposes. One of these proteins is DrrA. Earlier related studies indicate that the DrrA successful redirecting the material transport in human cells in direction the pathogen, well known with the aid of so-called Rab proteins for this purpose.